FOLH1 and prostate cancer: GRPr and PSMA expression were compared on primary prostate cancer samples (Schollhammer et al. 2019; Touijer et al. 2019) as well as patients (Baratto et al. 2020) providing evidence that the biodstribution for the two radioligands were distinct.